Crisnatol mesylate  (Synonyms: BWA770U mesylate)

Crisnatol (BWA770U) mesylate is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol mesylate shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts^[1][2][3].

Crisnatol (1.3 μg/mL; 24-72 h) mesylate inhibits the replication of HepG2 cells, decreases cell viability by 35%^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Crisnatol (25 mg/kg; p.o.; single dose) mesylate shows oral activity and shows stable metabolite profile extract of rat feces by autoradiography^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

441.54

C₂₄H₂₇NO₅S

96389-69-4

OCC(C)(NCC1=C2C=CC=CC2=C3C(C4=CC=CC=C4C=C3)=C1)CO.OS(=O)(C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Adams DJ. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. Cancer Res. 1989 Dec 1;49(23):6615-20.  [Content Brief]

  [2]. Patel DK, et al. Metabolism of a novel antitumor agent, crisnatol, by a human hepatoma cell line, Hep G2, and hepatic microsomes. Characterization of metabolites. Biochem Pharmacol. 1991 Jul 5;42(2):337-46.  [Content Brief]

  [3]. Patel DK, et al. Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat. Drug Metab Dispos. 1991 Mar-Apr;19(2):491-7.  [Content Brief]